Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration


If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD


Acceptance of BLA Will Trigger $20...

Related Keywords

California ,United States ,Ukraine ,Denver ,Colorado ,Pascal Touchon ,Pierre Fabre ,Securities Exchange ,Linkedin ,Memorial Sloan Kettering Cancer Center ,Atara Biotherapeutics Inc ,Exchange Commission ,Drug Administration ,Nasdaq ,Biologics License Application ,Chief Executive Officer ,Objective Response Rate ,Securities Act ,Securities Exchange Act ,Pierre Fabre Laboratories ,Middle East ,Southern California ,Financial Condition ,